drugset / Trial / NCT04409483
Evaluation of Additional Treatments for COVID-19: a Randomized Trial in Niger
Phase 3
Withdrawn
Epicentre
Centre de Recherche Médicale et Sanitaire · collabMinistry of Public Health, Republic of Niger · collabUniversité Abdou Moumouni · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess whether lopinavir/ritonavir (or eventually other antiviral drugs) is effective at reducing the rate of hospitalization among confirmed COVID-19 cases treated as outpatients.
Timeline
- Start
- 2020-06-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 400 mg | Oral |
| Subject | Ritonavir | Other / unclassified | 100 mg | Oral |
| Background | Acetaminophen | Small molecule | — | — |
| Background | Vitamin C | Other / unclassified | 1000 mg | — |